SuperworthOdyssey Therapeutics free cash flow ODTX
Cash from operations less capital spending, by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$34.7M
Odyssey Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$34.7M.
Free cash flow over time
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$34.7M | n/a | |
| Q1 FY26 | −$41.2M | n/a | |
| Q2 FY25 | −$34.3M | n/a | |
| Q1 FY25 | −$39.5M | n/a |
Against its peers
Companies in Biotechnology nearest Odyssey Therapeutics' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| ODTXOdyssey Therapeutics | n/m |
| MGTXMeiraGTx | 1.2% |
| VCELVericel | 2.8% |
| ADMAAdma Biologics | 4.9% |
| PLXProtalix BioTherapeutics | 3.7% |
| KRYSKrystal Biotech | 2.8% |
| Peer median | 2.8% |
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Odyssey Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.